Evidence map›Paper›PMID 36838930›Full record

ArticleMolecules (Basel, Switzerland)2023

Enhanced Bioactive Potential of Functionalized Injectable Platelet-Rich Plasma.

Emoke Pall, Alexandra Roman, Diana Olah, Florin Ioan Beteg, Mihai Cenariu, Marina Spînu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Antibiotics (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. New Copper Complexes with Antibacterial and Cytotoxic Activity.International journal of molecular sciences · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Emoke PallDepartment of Clinical Sciences, University of Agricultural Sciences and Veterinary Medicine, 400374 Cluj-Napoca, Romania.ORCID 0000-0002-7919-7381
Alexandra RomanDepartment of Periodontology, Faculty of Dental Medicine, Iuliu Haţieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Diana OlahDepartment of Clinical Sciences, University of Agricultural Sciences and Veterinary Medicine, 400374 Cluj-Napoca, Romania.
Florin Ioan BetegDepartment of Clinical Sciences, University of Agricultural Sciences and Veterinary Medicine, 400374 Cluj-Napoca, Romania.
Mihai CenariuDepartment of Clinical Sciences, University of Agricultural Sciences and Veterinary Medicine, 400374 Cluj-Napoca, Romania.
Marina SpînuDepartment of Clinical Sciences, University of Agricultural Sciences and Veterinary Medicine, 400374 Cluj-Napoca, Romania.ORCID 0000-0003-0005-9638
University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca · ROIuliu Hațieganu University of Medicine and Pharmacy · RO

Funding

University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca 21866/04.10.2021
6 · The paper itself

Abstract

Injectable platelet-rich fibrin (iPRF) is a frequently used platelet concentrate used for various medical purposes both in veterinary and human medicine due to the regenerative potential of hard and soft tissues, and also because of its antimicrobial effectiveness. This in vitro study was carried out to assess the cumulative antimicrobial and antibiofilm effect of iPRF functionalized with a multifunctional glycoprotein, human lactoferrin (Lf). Thus, the ability to potentiate cell proliferation was tested on keratinocytes and evaluated by the CCK8 test. The combinations of iPRF and Lf induced an increase in the proliferation rate after 24 h. The average cell viability of treated cultures (all nine variants) was 102.87% ± 1.00, and the growth tendency was maintained even at 48 h. The highest proliferation rate was observed in cultures treated with 7% iPRF in combination with 50 µg/mL of Lf, with an average viability of 102.40% ± 0.80. The antibacterial and antibiofilm activity of iPRF, of human lactoferrin and their combination were tested by agar-well diffusion (Kirby-Bauer assay), broth microdilution, and crystal violet assay against five reference bacterial strains. iPRF showed antimicrobial and antibiofilm potential, but with variations depending on the tested bacterial strain. The global analysis of the results indicates an increased antimicrobial potential at the highest concentration of Lf mixed with iPRF. The study findings confirmed the hypothesized enhanced bioactive properties of functionalized iPRF against both Gram-positive and Gram-negative biofilm-producing bacteria. These findings could be further applied, but additional studies are needed to evaluate the mechanisms that are involved in these specific bioactive properties.

Indexed as

Anti-Infective AgentsPlatelet-Rich PlasmaAnti-Bacterial AgentsBacteriaGram-Negative BacteriaHumansLactoferrinAnti-Bacterial AgentsAnti-Infective AgentsLactoferrinantibiofilmantimicrobialhuman lactoferrininjectable platelet-rich plasmaproliferation

Identifiers

PMID36838930
PMCPMC9967773
OpenAlexW4321375808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.